EORTC Leukemia Group Trials on Acute Myeloid Leukemias: An Overview
Originally designated as the Leukemia and Hematosarcoma Group, the EORTC Leukemia Group is one of the oldest of cooperative groups. It was created by Prof. G. Mathe in 1964 and been chaired since then by: G. Marchal (France), J. Bousser (France), W. F. Stenfert-Kroese (Netherlands), J. S. Malpas (United Kingdom), J. Bernard (France), H. O. Klein (Federal Republic of Germany), J. Revol (France), C. Hannen (Netherlands), P. Strychmans (Belgium), and R. Zittoun (France). This group has focused its efforts on the treatment of acute myeloid leukemia (AML). The objective of the present chapter is to present an overview of the trials hitherto conducted and the policy adopted for the ongoing trials on AML.
KeywordsToxicity Hepatitis Leukemia Doxorubicin Methotrexate
Unable to display preview. Download preview PDF.
- 3.Hayat M, Jehn U, Willemze R, Haanen C, Zittoun R, Monconduit M, Lowenberg B, Stryckmans P, Peetermans M, De Cataldo F, Kerkhofs H, Abels J, Klein HO, Andrien J, Goudsmit R, Cauchie C, Suciu S, Solbu G (1986) A randomized comparison of maintenance treatment with androgens, immunotherapy, and chemotherapy in adult acute myelogenous leukemia. Cancer 58: 617–623PubMedCrossRefGoogle Scholar
- 5.Leukaemia and Hematosarcoma Cooperative Group of the E.O.R.T.C. (1973) A comparative trial of remission induction (by cytosine arabinoside, or C.A.R. and thioguanine, or C.A.R. and daunorubicine) and maintenance therapy (by C.A.R. or methylgag) in acute myeloid leukaemia. Biomedicine (Paris) 18: 192–198Google Scholar
- 6.Leukaemia and Haematosarcoma Cooperative Group of the E.O.R.T.C. (1974) A second comparative trial of remission induction (by cytosine arabinoside given every 12 hours, or C.A.R. and thioguanine, or C.A.R. and danorubicine) and maintenance therapy (by C.A.R. or methylgag) in acute myeloid leukaemia. Eur J Cancer 10: 413–418Google Scholar
- 9.Zittoun R, Cadiou M, Bayle C, Suciu S, Solbu G, Hayat M and the E.O.R.T.C. Leukaemia and Hematosarcoma Cooperative Group (1984) Prognostic value of cytologic parameters in acute myelogenous leukemia. Cancer 53: 1526–1532Google Scholar